acebutolol has been researched along with Myocardial Infarction in 21 studies
Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.
acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The APSI trial was a randomized placebo-controlled trial designed to assess the efficacy of 1 year of treatment by acebutolol in high-risk patients who had survived an acute myocardial infarction." | 9.08 | Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'Infarctus. ( Boissel, JP; Cucherat, M; Leizorovicz, A, 1997) |
| "Acebutolol et Prévention Secondaire de l'Infarctus (APSI), a randomized, placebo-controlled trial, was designed to test long-term acebutolol, 200 mg twice daily, a beta blocker with mild intrinsic sympathomimetic activity, in the prevention of late death in high-risk postacute myocardial infarction (AMI) patients." | 9.06 | Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. ( Boissel, JP; Leizorovicz, A; Peyrieux, JC; Picolet, H, 1990) |
| "A randomized, placebo-controlled trial was carried out to determine the effectiveness of acebutolol in preventing late death in high-risk patients surviving an acute myocardial infarction (MI)." | 9.06 | Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators. ( Boissel, JP; Ducruet, T; Leizorovicz, A; Picolet, H, 1990) |
| "Plasma atrial natriuretic peptide (ANP) was measured during dynamic exercise in 10 patients with coronary heart disease before and after single dose atenolol 50 mg and acebutolol 200 mg, respectively." | 9.06 | Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol. ( Keller, N; Larsen, J; Storm, T; Sykulski, R; Thamsborg, G, 1988) |
| "The relevance of the ancillary pharmacological properties of intrinsic sympathomimetic activity (ISA) and cardioselectivity to the haemodynamic profile following intravenous beta-blockade was examined in a randomised study of propranolol (16 mg), acebutolol (160 mg) or penbutolol (4 mg) in 30 patients with stable angina pectoris." | 9.05 | Comparative haemodynamic dose-response effects of intravenous propranolol, acebutolol and penbutolol in angina pectoris. ( Ahuja, RC; Hussain, M; Nelson, GI; Okoli, RC; Silke, B; Taylor, SH; Verma, SP, 1984) |
| "The hemodynamic dose-response effects of intravenous (25 and 50 mg) and oral (200 and 400 mg) acebutolol were compared in a randomized between-group study in men within 17 hours of an acute uncomplicated myocardial infarction." | 9.05 | Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction. ( Baliga, G; Clarke, J; Nelson, G; Silke, B; Taylor, SH; Verma, SP, 1985) |
| "The haemodynamic tolerance of intravenous acebutolol was evaluated during the acute phase of myocardial infarction." | 7.67 | [Hemodynamic effects of intravenous acebutolol in the acute phase of myocardial infarction]. ( Adams, C; Baubion, N; Le Pailleur, C; Meilhac, B; Metzger, JP; Montgermont, P; N'Koua, JL; Vacheron, A, 1985) |
| "To assess the effects of intravenously administered acebutolol (1-20 mg every 4 hours for 24 hours) on cardiac rhythm and performance, we studied 72 patients with evolving myocardial infarction." | 7.66 | Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. ( Ahumada, GG; Ambos, HD; Jaffe, AS; Karlsberg, RP; Roberts, R; Sobel, BE, 1979) |
| "The APSI trial was a randomized placebo-controlled trial designed to assess the efficacy of 1 year of treatment by acebutolol in high-risk patients who had survived an acute myocardial infarction." | 5.08 | Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'Infarctus. ( Boissel, JP; Cucherat, M; Leizorovicz, A, 1997) |
| "Acebutolol et Prévention Secondaire de l'Infarctus (APSI), a randomized, placebo-controlled trial, was designed to test long-term acebutolol, 200 mg twice daily, a beta blocker with mild intrinsic sympathomimetic activity, in the prevention of late death in high-risk postacute myocardial infarction (AMI) patients." | 5.06 | Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. ( Boissel, JP; Leizorovicz, A; Peyrieux, JC; Picolet, H, 1990) |
| "A randomized, placebo-controlled trial was carried out to determine the effectiveness of acebutolol in preventing late death in high-risk patients surviving an acute myocardial infarction (MI)." | 5.06 | Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators. ( Boissel, JP; Ducruet, T; Leizorovicz, A; Picolet, H, 1990) |
| "Plasma atrial natriuretic peptide (ANP) was measured during dynamic exercise in 10 patients with coronary heart disease before and after single dose atenolol 50 mg and acebutolol 200 mg, respectively." | 5.06 | Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol. ( Keller, N; Larsen, J; Storm, T; Sykulski, R; Thamsborg, G, 1988) |
| "The relevance of the ancillary pharmacological properties of intrinsic sympathomimetic activity (ISA) and cardioselectivity to the haemodynamic profile following intravenous beta-blockade was examined in a randomised study of propranolol (16 mg), acebutolol (160 mg) or penbutolol (4 mg) in 30 patients with stable angina pectoris." | 5.05 | Comparative haemodynamic dose-response effects of intravenous propranolol, acebutolol and penbutolol in angina pectoris. ( Ahuja, RC; Hussain, M; Nelson, GI; Okoli, RC; Silke, B; Taylor, SH; Verma, SP, 1984) |
| "The hemodynamic dose-response effects of intravenous (25 and 50 mg) and oral (200 and 400 mg) acebutolol were compared in a randomized between-group study in men within 17 hours of an acute uncomplicated myocardial infarction." | 5.05 | Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction. ( Baliga, G; Clarke, J; Nelson, G; Silke, B; Taylor, SH; Verma, SP, 1985) |
| "The haemodynamic tolerance of intravenous acebutolol was evaluated during the acute phase of myocardial infarction." | 3.67 | [Hemodynamic effects of intravenous acebutolol in the acute phase of myocardial infarction]. ( Adams, C; Baubion, N; Le Pailleur, C; Meilhac, B; Metzger, JP; Montgermont, P; N'Koua, JL; Vacheron, A, 1985) |
| "To assess the effects of intravenously administered acebutolol (1-20 mg every 4 hours for 24 hours) on cardiac rhythm and performance, we studied 72 patients with evolving myocardial infarction." | 3.66 | Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. ( Ahumada, GG; Ambos, HD; Jaffe, AS; Karlsberg, RP; Roberts, R; Sobel, BE, 1979) |
| "Acute myocardial infarction is characterized by a more pronounced rise in plasma ANP concentration in hypertensive patients than in those without a history of hypertension." | 1.29 | Elevated plasma atrial natriuretic peptide concentrations in hypertensive patients with acute myocardial infarction. ( Górecki, A; Ignatowska-Switalska, H; Januszewicz, A; Kochanowski, J; Lapiński, M; Opolski, G; Stolarz, P; Słomka, K; Wocial, B, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (66.67) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rinfret, S | 1 |
| Abrahamowicz, M | 1 |
| Tu, J | 1 |
| Humphries, K | 1 |
| Eisenberg, MJ | 1 |
| Richard, H | 1 |
| Austin, PC | 1 |
| Pilote, L | 1 |
| Wan, SH | 1 |
| Seah, CS | 1 |
| Teh, LB | 1 |
| Letchmana, K | 1 |
| Azancot, I | 2 |
| Lorente, P | 1 |
| Georgiopoulos, G | 2 |
| Beaufils, P | 2 |
| Masquet, C | 2 |
| Baudouy, Y | 1 |
| Slama, R | 1 |
| Bory, M | 1 |
| Bénichou, M | 1 |
| Guiomard, A | 1 |
| Zygelman, M | 1 |
| Evstigneff, T | 1 |
| Bréaud, N | 1 |
| Roland, E | 1 |
| Pansard, Y | 1 |
| Mérillon, JP | 1 |
| Gourgon, R | 1 |
| Silke, B | 2 |
| Nelson, GI | 1 |
| Verma, SP | 2 |
| Ahuja, RC | 1 |
| Okoli, RC | 1 |
| Hussain, M | 1 |
| Taylor, SH | 2 |
| Górecki, A | 1 |
| Januszewicz, A | 1 |
| Opolski, G | 1 |
| Lapiński, M | 1 |
| Wocial, B | 1 |
| Ignatowska-Switalska, H | 1 |
| Słomka, K | 1 |
| Kochanowski, J | 1 |
| Stolarz, P | 1 |
| Cucherat, M | 1 |
| Boissel, JP | 3 |
| Leizorovicz, A | 3 |
| Tashchuk, VK | 1 |
| Polishchuk, OIu | 1 |
| Hrechko, SI | 1 |
| Makoviĭchuk, IO | 1 |
| Polians'ka, OS | 1 |
| Turubarova, NA | 1 |
| Chaplyns'kyĭ, RB | 1 |
| Sokur, IV | 1 |
| Bouvrain, Y | 1 |
| Thuillier, P | 1 |
| Gradman, AH | 1 |
| Winkle, RA | 1 |
| Fitzgerald, JW | 1 |
| Meffin, PJ | 1 |
| Stoner, J | 1 |
| Bell, PA | 1 |
| Harrison, DC | 1 |
| Schroeder, JS | 1 |
| Ahumada, GG | 1 |
| Karlsberg, RP | 1 |
| Jaffe, AS | 1 |
| Ambos, HD | 1 |
| Sobel, BE | 1 |
| Roberts, R | 1 |
| Jaillon, P | 1 |
| Picolet, H | 2 |
| Peyrieux, JC | 1 |
| Ducruet, T | 1 |
| Kiricuta, IC | 1 |
| Schmitt, WG | 1 |
| Beyer, HK | 1 |
| Keller, N | 1 |
| Sykulski, R | 1 |
| Thamsborg, G | 1 |
| Storm, T | 1 |
| Larsen, J | 1 |
| Jardine, RM | 1 |
| Obel, IW | 1 |
| Smith, AM | 1 |
| Metzger, JP | 1 |
| Montgermont, P | 1 |
| N'Koua, JL | 1 |
| Baubion, N | 1 |
| Adams, C | 1 |
| Meilhac, B | 1 |
| Le Pailleur, C | 1 |
| Vacheron, A | 1 |
| Nelson, G | 1 |
| Clarke, J | 1 |
| Baliga, G | 1 |
2 reviews available for acebutolol and Myocardial Infarction
| Article | Year |
|---|---|
Relevance of intrinsic sympathomimetic activity for beta blockers.
Topics: Acebutolol; Adrenergic beta-Antagonists; Animals; Blood Circulation; Cardiac Output; Catecholamines; | 1990 |
[Possibilities of phosphorus 31 spectroscopy in assessing the therapeutic effects on cellular energy metabolism of the myocardium].
Topics: Acebutolol; Cardioplegic Solutions; Chlorpromazine; Energy Metabolism; Humans; Magnetic Resonance Sp | 1989 |
9 trials available for acebutolol and Myocardial Infarction
| Article | Year |
|---|---|
Effects of acebutolol on myocardial infarct extension: a randomized electrocardiographic, enzymatic and angiographic study.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Cineangiography; Clinical Trials as Topic; Coronary | 1982 |
Comparative haemodynamic dose-response effects of intravenous propranolol, acebutolol and penbutolol in angina pectoris.
Topics: Acebutolol; Adult; Angina Pectoris; Clinical Trials as Topic; Dose-Response Relationship, Drug; Exer | 1984 |
Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'Infarctus.
Topics: Acebutolol; Actuarial Analysis; Adrenergic beta-Antagonists; Cause of Death; Follow-Up Studies; Fran | 1997 |
[Value of beta-blockers during the acute phase of myocardial infarction. Actual status of the question and methodology].
Topics: Acebutolol; Adrenergic beta-Antagonists; Aged; Angiography; Clinical Trials as Topic; Humans; Myocar | 1978 |
Newer antiarrhythmic agents for patients with coronary artery disease.
Topics: Acebutolol; Adult; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; | 1978 |
Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol.
Topics: Acebutolol; Administration, Oral; Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multic | 1990 |
Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators.
Topics: Acebutolol; Algorithms; Contraindications; Double-Blind Method; Female; Humans; Male; Middle Aged; M | 1990 |
Atrial natriuretic peptide during exercise in patients with coronary heart disease before and after single dose atenolol and acebutolol.
Topics: Acebutolol; Aged; Atenolol; Atrial Natriuretic Factor; Clinical Trials as Topic; Coronary Disease; E | 1988 |
Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction.
Topics: Acebutolol; Administration, Oral; Adult; Analysis of Variance; Chromatography, High Pressure Liquid; | 1985 |
10 other studies available for acebutolol and Myocardial Infarction
| Article | Year |
|---|---|
A population-based analysis of the class effect of beta-blockers after myocardial infarction.
Topics: Acebutolol; Adrenergic beta-Antagonists; Aged; Atenolol; Female; Humans; Male; Metoprolol; Myocardia | 2007 |
Haemodynamic profile of acebutolol in acute myocardial infarction.
Topics: Acebutolol; Adrenergic beta-Antagonists; Hemodynamics; Humans; Injections, Intravenous; Middle Aged; | 1980 |
[Comparison of the action of beta-blockers and calcium inhibitors in the treatment of primary angina pectoris].
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Angina Pectoris; Calcium Channel Blockers; Coronary | 1983 |
[Hemodynamic and coronary metabolic effects of the cold test before and after acebutolol].
Topics: Acebutolol; Adrenergic beta-Antagonists; Blood Pressure; Cardiac Pacing, Artificial; Coronary Circul | 1983 |
Elevated plasma atrial natriuretic peptide concentrations in hypertensive patients with acute myocardial infarction.
Topics: Acebutolol; Adult; Aged; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output, Low; Creatine Ki | 1995 |
[The objective assessment of treatment efficacy in microfocal myocardial infarct using paired stress tests].
Topics: Acebutolol; Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiac Pacing, Artificial; Dilti | 1998 |
Suppression of premature ventricular contractions by acebutolol.
Topics: Acebutolol; Aged; Cardiac Complexes, Premature; Drug Evaluation; Electrocardiography; Female; Heart | 1977 |
Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction.
Topics: Acebutolol; Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Creatine Kinase; Electrocardiography; | 1979 |
Intravenous acebutolol raises serum potassium in acute myocardial infarction.
Topics: Acebutolol; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Aged; Myocardial Infarction; Po | 1986 |
[Hemodynamic effects of intravenous acebutolol in the acute phase of myocardial infarction].
Topics: Acebutolol; Aged; Hemodynamics; Humans; Infusions, Parenteral; Middle Aged; Myocardial Infarction | 1985 |